|Bid||0.00 x 800|
|Ask||0.00 x 2200|
|Day's Range||79.15 - 80.03|
|52 Week Range||52.83 - 80.19|
|Beta (3Y Monthly)||0.38|
|PE Ratio (TTM)||34.41|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||2.20 (2.78%)|
|1y Target Est||82.81|
NEW YORK , Feb. 21, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Immune Design Corp. (NASDAQ: IMDZ) and its board of directors for breach of fiduciary duty concerning ...
NEW YORK, Feb. 21, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Immune Design Corp. (“Immune Design”.
Biotech M&A is on a roll in 2019, with a couple of multi-billion dollar deals announced already, including Bristol-Myers Squibb Co (NYSE: BMY )'s proposed buy of Celgene Corporation (NASDAQ: CELG ) and ...
Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
SAN DIEGO , Feb. 21, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immune Design Corp. (NASDAQ: IMDZ) ("Immune ...
Merck & Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs. Merck will pay $5.85 in cash for each share of Immune ...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
In a collaboration announced Tuesday, Keytruda will be tested with Torque's T-cell therapy against several cancers.
shares slipped lower in pre-market trading Wednesday after the drugmaker said one of its key liver cancer treatments failed a late-stage trial only months after getting accelerated approval from the U.S. Food & Drug Administration. Merck said late Tuesday that its Keytruda treatment for patients with advanced liver cancer who were previously treated with systemic therapy did not meet the endpoints for overall survival when compared with placebo plus best supportive care. "While we are disappointed KEYNOTE-240 did not meet its co-primary endpoints, the results for overall survival, progression-free survival and objective response rate are generally consistent with findings from the Phase 2 study, which led to the accelerated approval of KEYTRUDA for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib," said chief medical officer Dr. Roy Baynes.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 19) Alector Inc (NASDAQ: ALEC ) (IPOed early February) ...
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Marks First Application for KEYTRUDA in SCLC
Chairman, President & CEO of Merck & Co Inc (NYSE:MRK) Kenneth C Frazier sold 135,613 shares of MRK on 02/19/2019 at an average price of $80.03 a share.
Merck & Co Inc's cancer drug Keytruda failed a late-stage trial's main goals of slowing disease progression and extending the life of patients with a common type of liver cancer, the company said on Tuesday. The results could hamper prospects for the drug, which had received an accelerated approval from the U.S. Food and Drug Administration in November as a treatment for patients with advanced liver cancer who had been previously treated with Bayer AG's Nexavar. Keytruda, which is approved to treat several forms of cancer including skin and lung cancer, is Merck's biggest drug and brought in revenue of $7.17 billion last year.
Merck & Co. Inc. shares declined in after-hours trading Tuesday after the company announced that a study of its Keytruda drug did not meet its goals. The company said that a study on the effectiveness of the drug for patients with a specific type of liver cancer did not reach its defined goals for survival. Merck is testing the drug on a variety of cancers in a big bet on immunotherapy for cancer. Merck shares dipped slightly more than 1% in the extended session after making the announcement, following a 0.7% decline in the regular session. The stock has gained 40.8% in the past 12 months as the S&P 500 index has gained 1.6%.
Merck , known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-240 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy, did not meet its co-primary endpoints of overall survival and progression-free survival ...
Merck & Co Inc NYSE:MRKView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MRK with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $10.04 billion. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. MRK credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
U.S. Approval Based on Significant Recurrence-Free Survival Benefit Demonstrated with KEYTRUDA in Phase 3 EORTC1325/KEYNOTE-054 Trial
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Today I will be providing a simple run through ofRead More...